Purpose
The Developmental therapeutics committee’s purpose is to support the design and development of novel Phase I and II studies to identify the dose, schedule and preliminary efficacy of novel therapeutic approaches with the goal to advance safe and effective novel therapies into Phase 2 and 3 studies. Our studies include traditional phase I and II studies, window-of-opportunity studies, neoadjuvant therapy studies, and novel therapeutic designs. We support the development of translational and correlative studies to advance the science behind these novel therapeutic options. We strive to educate, include and support (early) investigators in drug development, design and conduct of early phase clinical trials.
The full committee meets 2 times per year during the NRG Oncology semi-annual in-person meetings. The Core Committee additionally meets with two virtual interim meetings in between the semi-annual NRG Oncology meetings. Study-specific meetings occur on a weekly/bi-weekly basis, and depending on the phase of development.